Phase
Condition
Liver Disease
Hepatitis
Liver Disorders
Treatment
placebo
zetomipzomib in open-label extension
zetomipzomib
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria for the Double-blind Treatment Period:
Must be aged ≥18 years.
Must have a clinical diagnosis of AIH and signs of active disease despite standard-of-care therapy for ≥3 months or disease flare after experiencing complete remission induced by standard-of-care treatment, including:
Screening ALT values that are 1.25 to 10 times the upper limit of the normal range (ULN)
Liver biopsy results with Ishak score (modified HAI) ≥5/18 indicating active AIH, from a biopsy performed at Screening, or within 6 months prior to Screening
Mild or no hepatic impairment (Child Pugh category A)
Must be willing to use and taper glucocorticoid therapy.
Must be willing to use effective contraception.
Key Exclusion Criteria for the Double-blind Treatment Period:
Have a concomitant diagnosis of primary biliary sclerosis, primary sclerosing cholangitis, IgG 4 related cholangitis, drug related AIH (at Screening) or a history of drug-related AIH.
Have clinical evidence of significant unstable or uncontrolled diseases other than the disease under study.
Are receiving oral or injectable immunomodulating treatment for any other autoimmune disease prior to enrollment in the study. Patients who have been using such treatments must follow the specified washout periods.
Have an active infection (eg, acute hepatitis E, cytomegalovirus, or Epstein-Barr virus) requiring systemic therapy with antibiotic, antiviral, or antifungal treatment, or has had any febrile illness within 7 days prior to Day -1.
Have a history of thyroiditis, celiac disease, or other autoimmune disorder known to be associated with transaminitis.
Have liver cirrhosis with significant impairment of liver function (Child Pugh category B or C) or have decompensated cirrhosis.
Patients with histology confirmed coincident non-alcoholic steatohepatitis.
Key Inclusion Criteria for the Open-label Extension Period:
Same as Double-blind Treatment Period inclusion criteria, except the following modifications:
ALT value can be normal or, if elevated, in the range of 1.25 to 10 times the upper limit of normal
Must have completed the Double-blind Period study visits through Week 24, including all Week 24 Visit assessments.
Must be willing to maintain glucocorticoid therapy or continue to taper glucocorticoid therapy.
Key Exclusion Criteria for the Open-label Extension Period:
• Same as Double-blind Treatment Period except no need to re-test for HIV, HBV, HCV, and TB.
Study Design
Study Description
Connect with a study center
Mayo Clinic Arizona
Phoenix 5308655, Arizona 5551752 85054
United StatesSite Not Available
Keck School of Medicine of USC
Los Angeles 5368361, California 5332921 90033
United StatesSite Not Available
University of California, Los Angeles
Los Angeles 5368361, California 5332921 90095
United StatesSite Not Available
Stanford Medicine
Redwood City 5386834, California 5332921 94063
United StatesSite Not Available
California Pacific Medical Center
San Francisco 5391959, California 5332921 94109
United StatesSite Not Available
University of California, San Francisco
San Francisco 5391959, California 5332921 94132
United StatesSite Not Available
University of Colorado
Aurora 5412347, Colorado 5417618 80045
United StatesSite Not Available
Yale University
New Haven 4839366, Connecticut 4831725 06510
United StatesSite Not Available
Mayo Clinic Florida
Jacksonville 4160021, Florida 4155751 32224
United StatesSite Not Available
University of Miami
Miami 4164138, Florida 4155751 33136
United StatesSite Not Available
Northwestern University
Chicago 4887398, Illinois 4896861 60611
United StatesSite Not Available
Rush University
Chicago 4887398, Illinois 4896861 60612
United StatesSite Not Available
Indiana University
Indianapolis 4259418, Indiana 4921868 46202
United StatesSite Not Available
Ochsner Clinic Foundation
New Orleans 4335045, Louisiana 4331987 70121
United StatesSite Not Available
Beth Israel Deaconess Medical Center
Boston 4930956, Massachusetts 6254926 02215
United StatesSite Not Available
Massachusetts General Hospital
Boston 4930956, Massachusetts 6254926 02114
United StatesSite Not Available
University of Michigan Medical Center
Ann Arbor 4984247, Michigan 5001836 48109
United StatesSite Not Available
Washington University School of Medicine
St Louis 4407066, Missouri 4398678 63110
United StatesSite Not Available
Northwell Health Center for Liver Disease and Transplantation
Manhasset 5125766, New York 5128638 11030
United StatesSite Not Available
New York University Langone Health/Grossman School of Medicine
New York 5128581, New York 5128638 10016
United StatesSite Not Available
Duke University Medical Center
Durham 4464368, North Carolina 4482348 27710
United StatesSite Not Available
University Hospitals Cleveland Medical Center
Cleveland 5150529, Ohio 5165418 44106
United StatesSite Not Available
University of Pennsylvania
Philadelphia 4560349, Pennsylvania 6254927 19104
United StatesSite Not Available
Virginia Commonwealth University
Richmond 4781708, Virginia 6254928 23298
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.